This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis | MicrobiomeTrials
← Back to trials NCT07718529
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis Recruiting PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2027-01Est. Completion: 2030-01
Enrollment target: 224 participantsLocations CHU Amiens-Picardie, Amiens, France Centre Hospitalier d'Avignon, Avignon, France CHRU Besançon, Besançon, France CHU Bordeaux, Bordeaux, France CHU Clermont Ferrand, Clermont-Ferrand, France Chu Lille, Lille, France HCL, Lyon, France AP-HM hopital Nord, Marseille, France CHU Montpellier, Montpellier, France CHRU Nancy, Nancy, France CHU Nantes, Nantes, France CHU Nice, Nice, France CHU Nîmes, Nîmes, France Hôpital Beaujon, Paris, France Hôpital Bicêtre, Paris, France Hôpital Henri-Mondor, Paris, France Institut des MICI, Paris, France Chu Rennes, Rennes, France CHU Rouen, Rouen, France CHU St Etienne, Saint-Etienne, France Chits Toulon, Toulon, France CHU Toulouse, Toulouse, France
Other microbiome trials you might be interested in Ulcerative Colitis
The purpose of this research study is to test the efficacy and safety of the study intervention, CurQD or placebo (non-a…
New York, United States Est. completion Jun 23, 2027
Crohn Disease Colitis, Ulcerative
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sub…
San Diego, United States Est. completion Jan 5, 2026
Phase 2
Recruiting
Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the st…
New York, United States Est. completion Oct 2028